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BRAF is the main eﬀector of KRAS in the RAS-RAF-MAPK axis, a signaling pathway downstream of EGFR. The activation of
this cascade is an important pathway in cancer development and is considered a key pathway for therapeutic molecules. Recent
studies in metastatic colorectal cancer found that an oncogenic activation of BRAF by a point mutation in exon 15 (V600E) could
bypass the EGFR-initiated signaling cascade with the eﬀect that patients bearing the mutant BRAF allele are not likely to beneﬁt
from EGFR-targeted therapies. We designed an allele-speciﬁc PCR and screened 65 salivary gland carcinoma (SGC) of the main
histopathological types for the BRAF V600E mutation. All 65 SGC in this cohort (100%) presented the BRAF wildtype. In a
previous study, we found a KRAS wildtype in 98.5% of SGC. These ﬁndings imply that SGC rarely acquires mutations that result
in a constitutive activation of the signaling cascade downstream of EGFR and this pleads in favor of further therapeutic trials with
EGFR-targeting monoclonal antibodies.
Copyright © 2009 Regine Dahse et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Malignant salivary gland neoplasms account for <0.5% of all
malignancies and approximately 3–5% of all head and neck
cancers [1]. Progress in understanding the cell biology of
salivary gland carcinomas (SGCs) and detecting vulnerable
molecular pathways may lead to the development of new
targeted therapy options in these rare cancers with poor
prognosis. The EGFR signaling cascade is considered a possi-
blekeypathwayfortherapeuticmolecules.Anti-EGFRagents
include (I) monoclonal antibodies (cetuximab or erbitux,
panitumumab) which block the binding of natural EGFR
ligands like EGF or TGF-α resulting in inhibition of down-
streamsignal-transduction pathwaysand (II) smallmolecule
tyrosine kinase inhibitors (TKIs) which act by binding the
ATP pocket within the kinase domain of the EGFR and
impairing its catalytic activity (geﬁtinib, erlotinib, lapatinib).
Downstream signaling pathways triggered by EGFR include
the RAS-RAF-extracellular signal-regulated kinase/mitogen
activated protein kinase (MEK/MAPK) pathway, which is
mainly correlated to cell proliferation, and the P13K-PTEN-
AKT axis.
Recently, we were able to demonstrate that frequent
EGFR overexpression and the absence of drug-resistance
EGFRmutationsinSGCpleadinfavoroffurthertherapeutic
trials with EGFR-targeting monoclonal antibodies. One of
the signaling eﬀectors downstream of EGFR, KRAS, was
shown by us to be rarely mutated in SGC [2, 3]. Wildtype
KRAS is one of the clinically proven prerequisites for
a successful anti-EGFR therapy and therefore anti-EGFR
monoclonal antibodies are approved only for metastatic
colorectal cancer patients whose tumors display wildtype
KRAS.
In the absence of KRAS mutations, resistance to anti-
EGFR treatments could be caused by alterations of other
members of the RAS-RAF-MAPK pathway. BRAF (v-raf
murine sarcoma viral oncogene homolog B1), a serine/
threonine kinase, is the downstream eﬀector of KRAS in
the RAS-RAF-MAPK signaling pathway. A somatic mutation
(V600E) in exon 15 of BRAF has been identiﬁed in multiple
human cancers with a mutation rate of 66% in malignant
melanomas [4] and at lower frequency in other human
carcinomas. Recently, it was demonstrated that wildtype2 Journal of Biomedicine and Biotechnology
BRAF is required for the response of patients with metastatic
colorectal cancer to cetuximab and panitumumab [5].
The aim of this study was to determine the BRAF V600E
mutation frequency in a large cohort of SGCs of the main
histopathological types and to design an allele-speciﬁc PCR
as an eﬀective screening method.
2.MaterialsandMethods
2.1. Tissue Specimens. Surgically removed, formalin-ﬁxed
tumorsampleswereobtainedfrom65patients(35malesand
30femaleswithamedianageatdiagnosisof55years)treated
with the histopathological diagnosis of an SGC according
to the WHO classiﬁcation [6]. All patients received surgery
and postoperative radiation therapy in selected cases. EGFR-
targeted therapy was not applied. The study cohort consisted
of adenoid cystic carcinoma (n = 25) mucoepidermoid
carcinoma (n = 10), myoepithelial carcinoma (n = 8),
acinic cell carcinoma (n = 12) and adenocarcinoma ex
pleomorphic adenoma (n = 10).
2.2.DNAIsolation. GenomicDNAwasextractedandpooled
from oral mucosa samples of ﬁve healthy individuals. This
pooled DNA was used as a normal DNA control for the
development of the PCR assay. Heterozygous mutant control
DNA was extracted from cells of the colorectal cancer cell
line HT 29 which contains the heterozygous BRAF V600E
mutation. DNA from the tumor specimen was isolated after
microdissecting apprpriate tumor areas.
2.3. Design of an Allele-Speciﬁc PCR for the BRAF V600E
Mutation. The basis for discrimination using allele-speciﬁc
PCR is that a PCR primer mismatched at its 3  end with
the DNA template will react less eﬃciently than one that is
entirely complementary. Our allele-speciﬁc multiplex PCR
was designed with one common forward (BF) and two
separate reverse primers (BR and BMu):
BF: 5 -CTCTTCATAATGCTTGCTCTGATAGG-3 ,
BR: 5 -AGTTGAGACCTTCAATGACTTTCTAGT-3 ,
BMu: 5 -CCCACTCCATCGAGATTTCT-3 .
The forward primer BF and the reverse primer BR
amplify a 273bp fragment of both mutant and wildtype
alleles and thus serve as ampliﬁcation control. The second
reverse primer (BMu) is speciﬁc for the mutated allele at the
3  end. This primer together with BF generates an 143bp
product only in the presence of the V600E (GTG>GAG)
mutation (Figure 1(a)).
A series of annealing temperatures (52
◦C–60◦C), primer
concentrations (0.1–0.4μmol/L), and Mg2+ concentrations
(1.5–3.5mmol/L) were tested.
2.4. BRAF Mutational Analysis. PCR reactions for screening
S G Cw e r er u na taﬁ n a lv o l u m eo f2 5μL. Reactions consisted
of: 80–100ng genomic DNA; 200μmol/L dNTP; 0.1μmol/L
of primers; 1.5mmol/L MgCl2;0 . 5UTaq polymerase (Roche
Diagnostics, Penzberg, Germany). Final cycling conditions
were as follows: 5 minutes of denaturing at 94
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Figure 1: Allele-speciﬁc PCR for the detection of the BRAF V600E
mutation (2.5% agarose gel). (a) The 273bp fragment of both
mutant and wildtype alleles is always ampliﬁed and serves as
ampliﬁcation control. The smaller PCR product (143bp; arrow)
is ampliﬁed only in the presence of the V600E (GTG>GAG)
mutation. Lane 1: Molecular Weight marker; lane 2: heterozygous
mutant DNA control (HT 29); lane 3: homozygous wildtype DNA
control; lane 4: no template PCR control (water). Lanes 5–9:
analysis of tumor samples. The SGC samples in lanes 5–9 have
the BRAF V600E wildtype sequence. (b) Serial dilution of HT 29
DNA in normal wildtype DNA. The allele-speciﬁc PCR is able
to detect the 143bp mutation speciﬁc fragment in an 15-fold
excess of normal DNA. Lane 1: Molecular Weight marker; lane 2:
heterozygous mutant DNA control [HT 29] undiluted; lanes 3–9:
serial dilutions HT 29/WT DNA (starting from 1:2 up to1:64).
cycles of 94
◦C for 30 seconds, annealing 55
◦C for 45 seconds
and 72
◦C for 60 seconds. A volume of 10μL of the PCR
products was electrophoresed on a standard 2.5% agarosegel
stained with SYBR-Green I for visualization under UV light.
3. Results
The allele-speciﬁc PCR for the detection of the BRAF V600E
mutation demonstrated high speciﬁcity (i.e., detection of
only the normal or only the mutant allele), high sensitivity
(i.e., no spurious PCR fragments), and acceptable yield. All
65 SGC in this cohort (100%) presented the BRAF wildtype
(95% exact conﬁdence limit 0–0.07). The 273bp PCR
fragment was always ampliﬁed conﬁrming the integrity of
the isolated DNA from clinical tissue samples (Figure 1(a)).
To test the sensitivity of the mutation-speciﬁc PCR, we
made a serial dilution of HT 29 DNA (which contains
the heterozygous BRAF V600E mutation), in control DNA
with wildtype BRAF. Less than 6% of mutant DNA was
reproducibly detected (Figure 1(b)).
No BRAF V600E mutation was detected in additionally
screened DNA samples from microdissected normal tissue
adjacent to the tumor cells (5 cases).Journal of Biomedicine and Biotechnology 3
4. Discussion and Conclusions
The activation of the EGFR-RAS-RAF signaling cascade is an
important pathway in cancer development and is considered
a key pathway for therapeutic molecules. EGFR transmits
signals to the nuclei instructing cancer cells to proliferate
and metastasize, and KRAS and BRAF are those downstream
signaling molecules. Anti-EGFR therapies interrupt the
cancer-triggering signaling cascade, however, if the KRAS or
the BRAF gene is mutated, their proteins are locked into
an active conformation, regardless of whether the EGFR is
therapeutically blocked.
Cetuximab (erbitux) has already been tested in two
phase II studies in patients with recurrent and/or metastatic
SGC including mainly ACC, a cancer with generally poor
outcome.In50%ofpatients,clinicalbeneﬁt(i.e.,responseor
stablediseasefor6month)couldbeachieved[1,7].Geﬁtinib
wasassociated with a 53% stabledisease rate (10/19) in ACC,
but had no eﬀects on patients with salivary duct tumors and
mucoepidermoidcancer[8].Lapatinib,inhibitingErbB1and
ErbB2 tyrosine kinases, was studied in a phase II trial and
stabilized disease for greater than 6 months in 47% of ACC
patients [9].
Key molecules of the EGFR-RAS-RAF signaling cascade
and predictive markers of treatment outcome under anti-
EGFR therapies have not been comprehensively examined
in SGC. Investigations of the mutation status of proteins
in the cascade downstream of EGFR identiﬁed markers
for EGFR-targeted therapy in colorectal cancer. In recent
studies, wildtype BRAF as well as wildtype KRAS and intact
PTEN PIK3CA were found to be required for the response
of colorectal cancer patients treated with cetuximab or
panitumumab [5, 10, 11].
Wewereabletodemonstrateinthisandinaformerstudy
that KRAS and BRAF mutations seem to be extremely rare
in SGC. These ﬁndings imply that salivary gland carcinomas
which rarely acquire mutations that result in constitutive
activation of the signaling cascade downstream of EGFR
may be good candidates for anti-EGFR therapies. Molecular
analyses of alternative members of the EGFR signaling
cascade,suchasAkt-1andMEK-1,mayfurthercontributeto
elucidating predictive markers of treatment outcome under
anti-EGFR therapies in SGC.
Becauseofitsuniversalavailabilityasastandardmethod-
ology in molecular medicine, we designed a BRAF muta-
tion screening assay based on PCR. Allele-speciﬁc PCR,
also known as Ampliﬁcation Refractory Mutation System
(ARMS), is a well-established method for discriminating
between diﬀerent alleles at speciﬁc loci resulting from single
base mutations [12, 13]. We used the methodology to estab-
lish an assay with three PCR primers which allows the dis-
crimination of allele-speciﬁc PCR fragments by agarose gel
electrophoresis without the need of capillary electrophoresis
devices. With our assay, the speciﬁcity was incorporated
into the ampliﬁcation reaction itself. Interpretation of the
results can be made by simple visual inspection of the
stained gel to determine whether or not a speciﬁc primer
pair ampliﬁed a fragment with the template DNA. Because
microdissected tumor areas were used for the allele-speciﬁc
PCR, and a control ampliﬁcation was incorporated into
the PCR reaction to ensure DNA integrity, we can exclude
false negative results. So far, genomic screening for BRAF
mutations has been based mainly on direct sequencing. Our
protocol provides an alternative rapid, sensitive, and cost-
eﬀective BRAF screening method.
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